Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 2 1

Status

Recruiting 2Active not recruiting 1

Sponsor Class

INDUSTRY 2NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 70Tumor-Agnostic 3Head & Neck 3Gastrointestinal 3CNS 3Breast 3Plasma cell 2Other solid neoplasm 2Other hematologic neoplasm 2Lymphoid 2Gynecologic 2Genitourinary 2Endocrine 1Dermatologic 1

Conditions

Breast Neoplasms 3Lung Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Thyroid Neoplasms 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Rectal Neoplasms 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Multiple Myeloma 1Melanoma 1Lymphoma 1Hematologic Neoplasms 1Glioma 1Esophageal Neoplasms 1Endometrial Neoplasms 1Colorectal Neoplasms 1Colonic Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Hepatocellular 1

Interventions

Fulvestrant 83Letrozole 77Paclitaxel 76pembrolizumab 72Specimen Handling 66Trastuzumab 62Carboplatin 57Magnetic Resonance Spectroscopy 51ribociclib 49Capecitabine 48Anastrozole 47pertuzumab 46palbociclib 43exemestane 40abemaciclib 40Cyclophosphamide 40Tamoxifen 39Biopsy 38Docetaxel 30trastuzumab deruxtecan 29Taxes 28Radiotherapy 28Gemcitabine 25Blood Specimen Collection 25130-nm albumin-bound paclitaxel 25olaparib 22Surveys and Questionnaires 22Standard of Care 22sacituzumab govitecan 20eribulin 19

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
osimertinib × Breast × 90 days × Clear all
NCT02465060 2026-06-03

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

National Cancer Institute (NCI)

Phase 2 Active not recruiting
6,452 enrolled 1 FDA
BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidOther hematologic neoplasmPlasma cellThoracic

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Glioma, Carcinoma, Hepatocellular, Lung Neoplasms, Lymphoma, Melanoma, Multiple Myeloma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Rectal Neoplasms, Stomach Neoplasms, Thyroid Neoplasms, Uterine Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Hematologic Neoplasms

NCT06618287 2026-05-07

A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors

Bristol-Myers Squibb

Phase 1/2 Recruiting
416 enrolled
BreastThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Triple Negative Breast Neoplasms

NCT05785741 2026-04-06

A Study of DB-1310 in Advanced/Metastatic Solid Tumors

DualityBio Inc.

Phase 1/2 Recruiting
1,000 enrolled
BreastHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡